B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing ...

Verve Therapeutics VERV signed a definitive agreement with pharma bigwig Eli Lilly LLY. Per the terms, the pharma giant will ...

Eli Lilly has confirmed plans for a $1.3 billion takeover bid for Verve Therapeutics, upgrading a collaboration between the ...

Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment.

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Verve Therapeutics (NASDAQ: VERV), a biotechnology company with a market capitalization of nearly $1 billion, has been making significant strides in its clinical programs.The company’s ...

Find out if Verve Therapeutics Inc (VERV:XNAS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company ...